Cargando…

Efficacy and safety of recombinant human parathyroid hormone (1–34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis

The study evaluates efficacy and safety of recombinant human parathyroid hormone (1–34) [rhPTH (1–34)] and alendronate (ALN) in the treatment of postmenopausal osteoporosis. Totally 65 postmenopausal women with osteoporosis were divided into 2 groups. PTH group received daily subcutaneous injection...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deng, Jing, Feng, Zhengping, Li, Yue, Pan, Tingting, Li, Qifu, Zhao, Changhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392772/ https://www.ncbi.nlm.nih.gov/pubmed/30461654 http://dx.doi.org/10.1097/MD.0000000000013341

Ejemplares similares

Alendronate improves QOL of postmenopausal women with osteoporosis
por: Kawate, Hisaya, et al.
Publicado: (2010)

Efficacy of generic teriparatide and alendronate in Chinese postmenopausal women with osteoporosis: a prospective study
por: Li, Mei, et al.
Publicado: (2022)

Recombinant Human Parathyroid Hormone Related Protein 1-34 and 1-84 and Their Roles in Osteoporosis Treatment
por: Wang, Hua, et al.
Publicado: (2014)

Seven years’ experience with alendronate in postmenopausal Japanese women with osteoporosis
por: Iwamoto, Jun, et al.
Publicado: (2010)

Full length parathyroid hormone (1–84) in the treatment of osteoporosis in postmenopausal women
por: Jódar-Gimeno, Esteban
Publicado: (2007)

MON-378 Efficacy and Safety of Romosozumab vs Alendronate Is Similar Across Different Levels of Renal Function Among Postmenopausal Women with Osteoporosis
por: Miller, Paul, et al.
Publicado: (2020)

Anabolic Response of Intermittent Parathyroid Hormone and Alendronate on the Osteochondral Tissue of TMJ
por: Chen, Po-Jung, et al.
Publicado: (2022)

Effects of odanacatib on bone matrix mineralization in rhesus monkeys are similar to those of alendronate
por: Misof, Barbara M., et al.
Publicado: (2016)

Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis
por: Leder, Benjamin Z, et al.
Publicado: (2019)

Knowledge and compliance towards alendronate therapy among postmenopausal women with osteoporosis in Palestine
por: Radwan, Asma, et al.
Publicado: (2022)

Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature
por: Iwamoto, Jun, et al.
Publicado: (2008)

Cost-effectiveness of teriparatide compared with alendronate and risedronate for the treatment of postmenopausal osteoporosis patients in Iran
por: Ebadi Fard Azar, Amir Ali, et al.
Publicado: (2017)

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis
por: Bone, Henry G, et al.
Publicado: (2018)

ERRATUM for “Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis”
Publicado: (2020)

Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States
por: Le, Quang A., et al.
Publicado: (2018)

Nasal Administration and Plasma Pharmacokinetics of Parathyroid Hormone Peptide PTH 1-34 for the Treatment of Osteoporosis
por: Pearson, Richard G., et al.
Publicado: (2019)

Update on the efficacy, safety, and adherence to treatment of full length parathyroid hormone, PTH (1-84), in the treatment of postmenopausal osteoporosis
por: Pietrogrande, Luca
Publicado: (2010)

The combined effect of Parathyroid hormone (1–34) and whole-body Vibration exercise in the treatment of postmenopausal OSteoporosis (PaVOS study): a randomized controlled trial
por: Jepsen, D. B., et al.
Publicado: (2019)

Alendronate Sodium in the Management of Osteoporosis
por: Prinsloo, P J J, et al.
Publicado: (2006)

Single and Combined use of Human Parathyroid Hormone (PTH) (1-34) on Areal Bone Mineral Density (aBMD) in Postmenopausal Women with Osteoporosis: Evidence Based on 9 RCTs
por: Song, Jiefu, et al.
Publicado: (2014)

Vitamin D Boosts Alendronate Tail Effect on Bone Mineral Density in Postmenopausal Women with Osteoporosis
por: Catalano, Antonino, et al.
Publicado: (2021)

Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: A meta-analysis of randomized controlled trials
por: Wang, Ya-Kang, et al.
Publicado: (2017)

Effects of Intermittent Parathyroid Hormone 1–34 Administration on Circulating Mesenchymal Stem Cells in Postmenopausal Osteoporotic Women
por: Tang, Yutao, et al.
Publicado: (2019)

SUN-386 Treatment Outcomes of Intravenous Zoledronic Acid vs Oral Alendronate in Postmenopausal Women with Osteoporosis
por: Pyone, Zar Chi, et al.
Publicado: (2020)

Economic Evaluation of Oral Alendronate Therapy for Osteoporosis in Chinese Postmenopausal Women: The Impact of Medication Compliance and Persistence
por: You, Ruxu, et al.
Publicado: (2020)

Mechanistic PK-PD model of alendronate treatment of postmenopausal osteoporosis predicts bone site-specific response
por: Calvo-Gallego, José L., et al.
Publicado: (2022)

Influence of the Osteogenomic Profile in Response to Alendronate Therapy in Postmenopausal Women with Osteoporosis: A Retrospective Cohort Study
por: Villagómez Vega, Alejandra, et al.
Publicado: (2023)

Parathyroid hormone 1-34 and skeletal anabolic action: The use of parathyroid hormone in bone formation
por: Osagie-Clouard, L., et al.
Publicado: (2017)

The Efficacy and Safety of a Combined Alendronate and Calcitriol Agent (Maxmarvil): A Postmarketing Surveillance Study in Korean Postmenopausal Women with Osteoporosis
por: Suh, Hee-Won, et al.
Publicado: (2012)

Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy
por: Hiligsmann, M., et al.
Publicado: (2021)

Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis
por: Kim, Yeesuk, et al.
Publicado: (2020)

Similarities in Acquired Factors Related to Postmenopausal Osteoporosis and Sarcopenia
por: Sirola, Joonas, et al.
Publicado: (2011)

Endoscopic comparison of alendronate alone and the enteric-coated alendronate with calcitriol combination in postmenopausal Korean females
por: Mok, Ji Oh, et al.
Publicado: (2013)

Parathyroid Hormone Disturbances in Postmenopausal Women with Distal Forearm Fracture
por: Wihlborg, Axel, et al.
Publicado: (2021)

Hormone replacement therapy and the prevention of postmenopausal osteoporosis
por: Gambacciani, Marco, et al.
Publicado: (2014)

Five-year alendronate treatment outcome in older postmenopausal Japanese women with osteoporosis or osteopenia and clinical risk factors for fractures
por: Iwamoto, Jun, et al.
Publicado: (2009)

Effects of short-term combined treatment with alendronate and elcatonin on bone mineral density and bone turnover in postmenopausal women with osteoporosis
por: Iwamoto, Jun, et al.
Publicado: (2009)

Combination therapy of curcumin and alendronate modulates bone turnover markers and enhances bone mineral density in postmenopausal women with osteoporosis
por: Khanizadeh, Fatemeh, et al.
Publicado: (2018)

Efficacy and Safety of the Biosimilar Recombinant Human Parathyroid Hormone Cinnopar(®) in Postmenopausal Osteoporotic Women: A Randomized Double-blind Clinical Trial
por: TABATABAEI-MALAZY, Ozra, et al.
Publicado: (2018)

Effects of recombinant human parathyroid hormone (1-34) on cell proliferation, chemokine expression and the Hedgehog pathway in keratinocytes
por: Bu, Xiaolin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bm2lhrm2ua7e553nrk1auk14b0